Similar articles for PMID: 24649121

Year	Number of Results
2005	1
2007	1
2008	2
2009	2
2010	6
2011	7
2012	8
2013	8
2014	15
2015	15
2016	7
2017	7
2018	5
2019	12
2020	7
2021	4
2022	1
2024	0

1

Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001).

Nishimura R, Arima N, Toyoshima S, Ohi Y, Anan K, Sagara Y, Mitsuyama S, Tamura K. Nishimura R, et al. Mol Clin Oncol. 2013 Jan;1(1):47-52. doi: 10.3892/mco.2012.10. Epub 2012 Aug 9. Mol Clin Oncol. 2013. PMID: 24649121 Free PMC article.

2

Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Katayama K, Koga T, Kurashita K, Hasegawa S, Todoroki H, Kai Y, Ohi Y, Toyoshima S, Arima N, Mitsuyama S, Tamura K. Nishimura R, et al. Oncology. 2017;93(1):51-61. doi: 10.1159/000468521. Epub 2017 May 6. Oncology. 2017. PMID: 28478451

3

The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.

Wang Y, Liu Y, Du Y, Yin W, Lu J. Wang Y, et al. Curr Med Res Opin. 2013 Jun;29(6):633-42. doi: 10.1185/03007995.2013.794775. Epub 2013 Apr 22. Curr Med Res Opin. 2013. PMID: 23574264

4

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA. Perez EA, et al. BMC Cancer. 2019 May 30;19(1):517. doi: 10.1186/s12885-019-5687-0. BMC Cancer. 2019. PMID: 31146717 Free PMC article. Clinical Trial.

5

An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.

Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Iwase H. Sueta A, et al. PLoS One. 2014 Dec 26;9(12):e116054. doi: 10.1371/journal.pone.0116054. eCollection 2014. PLoS One. 2014. PMID: 25542038 Free PMC article.

6

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.

Tural D, Serdengecti S, Demirelli F, Öztürk T, İlvan S, Turna H, Özgüroglu M, Büyükünal E. Tural D, et al. Br J Cancer. 2014 Apr 15;110(8):1968-76. doi: 10.1038/bjc.2014.72. Epub 2014 Mar 4. Br J Cancer. 2014. PMID: 24595002 Free PMC article. Retracted.

7

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G. Razis E, et al. Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19. Breast Cancer Res Treat. 2011. PMID: 21594665 Free article.

8

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.

Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X. Wang L, et al. BMC Cancer. 2011 Jun 15;11:248. doi: 10.1186/1471-2407-11-248. BMC Cancer. 2011. PMID: 21676217 Free PMC article. Clinical Trial.

9

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, Santoni-Rugiu E, Andersson M, Ewertz M. Jensen JD, et al. Ann Oncol. 2012 Aug;23(8):2034-2042. doi: 10.1093/annonc/mdr546. Epub 2011 Dec 15. Ann Oncol. 2012. PMID: 22172323 Free article.

10

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. Esteva FJ, et al. Am J Pathol. 2010 Oct;177(4):1647-56. doi: 10.2353/ajpath.2010.090885. Epub 2010 Sep 2. Am J Pathol. 2010. PMID: 20813970 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

92 results

Results by year